New oral drug trial aims to slow scarring in fatal lung disease
NCT ID NCT07284459
Summary
This study is testing whether an oral medication called PIPE-791 can slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. About 324 adults with IPF will take either PIPE-791 or a placebo pill for 26 weeks to see if the drug helps preserve lung function. The main goal is to measure changes in breathing capacity and assess the drug's safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Anil Dhar Medicine Professional Corporation
RECRUITINGWindsor, Ontario, N8X 5A6, Canada
-
Dynamic Drug Advancement Ltd.
RECRUITINGAjax, Ontario, L1S 2J5, Canada
Conditions
Explore the condition pages connected to this study.